Skip to main
PCSA
PCSA logo

Processa Pharmaceuticals (PCSA) Stock Forecast & Price Target

Processa Pharmaceuticals (PCSA) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Processa Pharmaceuticals Inc. is projected to narrow its net loss per share estimate for 2026 to $0.15, an improvement from the previous estimate of $0.20, indicating enhanced financial management despite an increase in the outstanding share count. The anticipated positive interim data from the mid-stage trial of its NGC-Cap treatment is viewed as a potential significant value inflection point for the company. Additionally, the recent strategic investment and exploration of cryptocurrency treasury strategies suggest a proactive approach to enhancing financial stability and executing growth objectives.

Bears say

Processa Pharmaceuticals is projected to incur a significant net loss of $0.43 per share for the full year 2025, highlighting concerns about its financial sustainability. The company faces multiple risks, including potential delays in regulatory approvals, heightened competition which may lead to lower pricing and market penetration, and possible dilution risks that could negatively impact shareholder value. Additionally, a recent performance indicated a net loss of $0.25 per share, which, although close to earlier estimates, reaffirms the challenges the company faces in achieving profitability amidst a competitive landscape.

Processa Pharmaceuticals (PCSA) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Processa Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Processa Pharmaceuticals (PCSA) Forecast

Analysts have given Processa Pharmaceuticals (PCSA) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Processa Pharmaceuticals (PCSA) has a Strong Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Processa Pharmaceuticals (PCSA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.